Neoepitope BTLAP267L-specific TCR-T cell immunotherapy unlocks precision treatment for hepatocellular carcinoma
This preclinical study demonstrated the beneficial effects of neoepitope BTLA<sup>P267L</sup>-specific TCR-T cell immunotherapy, unlocking a novel strategy for personalized precision therapy in HCC.
Authors
- Yunbin Ye (ORCID: https://orcid.org/0000-0002-0256-987X)
- Suxin Wu
- Xin Lin
- Yang Wang (ORCID: https://orcid.org/0000-0002-3839-0003)
- Dong Zhou (ORCID: https://orcid.org/0000-0002-5436-6177)
- Hua Chen (ORCID: https://orcid.org/0000-0002-6331-7377)
- Fang Liu (ORCID: https://orcid.org/0000-0003-3456-160X)
- Xueqiang Zhao
- Mingji Zhang (ORCID: https://orcid.org/0000-0001-9531-5862)
- Rui Wei (ORCID: https://orcid.org/0000-0002-9913-832X)
- Chenlu Zhu (ORCID: https://orcid.org/0000-0001-7648-6893)
Institutions
- Fujian Medical University (CN)
- Fujian Provincial Cancer Hospital (CN)
- Tsinghua University (CN)
Publication Details
- Journal
- Cancer Biology and Medicine
- Published
- 2025-04-09
- DOI
- https://doi.org/10.20892/j.issn.2095-3941.2024.0434
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Natural Science Foundation of Fujian Province